Eidos Therapeutics completes $64M Series B financing

Funding supports Phase 2 clinical trials of AG10, a potential best-in-class therapy for transthyretin amyloidosis, and ongoing preparation for Phase 3 clinical trials

• Source: prnewswire
• 605
• April 10, 2018